8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Jan 20, 2026·SEC
Material company update
Jan 14, 2026·SEC
RAPT Therapeutics, Inc.(RAPT)Earnings, Financials & Key Ratios
RAPT•NASDAQ
$58.01
Price updated Jun 20, 2026
AboutRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$135M-7.2%
- Net Income-$130M-11.2%
- EPS (Diluted)-25.49-4.6%
- ROE-77.09%-29.4%
RAPT Price & Volume
RAPT Therapeutics, Inc. (RAPT) stock price & volume — 10-year historical chart
Loading chart...
Clinical Hold Stagnation Pressures RAPT Liquidity Runway
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Regulatory clinical hold uncertainty
Key Thesis Takeaways
- RAPT Therapeutics faces a binary risk profile as the ongoing FDA clinical hold on its lead asset, RPT193, continues to impede the validation of its CCR4 small molecule platform.
- With no revenue generation and a rapidly depleting cash balance, the company's long-term viability remains tethered to its ability to resolve safety concerns and secure additional funding.
- Investors should monitor the narrowing cash runway, which has fallen to $37.9 million as of 2025Q3, as the firm navigates significant operational losses.
Verdict Logic
the company's cash position has dwindled to $37.9 million as of 2025Q3, creating substantial uncertainty regarding its ability to fund operations through the resolution of the current FDA clinical hold.
RAPT Growth Metrics
RAPT Therapeutics, Inc. (RAPT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50.24%
Return on Capital
10 Years-59.56%
5 Years-57.23%
3 Years-60.38%
Last Year-79.25%
RAPT Recent Earnings
RAPT Therapeutics, Inc. (RAPT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
Mar 5, 2026Metric
Actual
Est
EPS
$9.12-1008.2%
$0.82
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.65+26.1%
$0.88
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.65-6.6%
$0.61
Rev
—
—
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$0.64+74.2%
$2.48
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $9.12vs $0.82-1008.2% | — |
| Q4 2025 | Nov 6, 2025 | $0.65vs $0.88+26.1% | — |
| Q3 2025 | Aug 7, 2025 | $0.65vs $0.61-6.6% | — |
| Q2 2025 | May 8, 2025 | $0.64vs $2.48+74.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for RAPT Therapeutics, Inc. (RAPT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $58.01 | $295.54M | -2.28 | — | — | -77.09% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $8.45 | $545.2M | -6.60 | -0.3% | -247.54% | -44.39% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — |
Compare RAPT vs Peers
RAPT Therapeutics, Inc. (RAPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RAPT SEC Filings & Documents
RAPT Therapeutics, Inc. (RAPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RAPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RAPT Frequently Asked Questions
RAPT Therapeutics, Inc. (RAPT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is RAPT profitable?
RAPT Therapeutics, Inc. (RAPT) reported a net loss of $105.6M for fiscal year 2024.
Dividend & Returns
What is RAPT's return on equity?
RAPT Therapeutics, Inc. (RAPT) has a return on equity (ROE) of -77.1%. Negative ROE indicates the company is unprofitable.
What is RAPT Therapeutics, Inc.'s free cash flow?
RAPT Therapeutics, Inc. (RAPT) had negative free cash flow of $86.7M in fiscal year 2024, likely due to heavy capital investments.